NewsRoom Articles - Page 37 of 218

TuesdayAug 06, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics

Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”) CNM-Au8(R), Clene’s lead drug candidate, is a fundamentally new approach for treating the underlying factors contributing to ALS, MS, and PD, by restoring neuronal health and function ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S. Clene (NASDAQ: CLNN), a pioneering biopharmaceutical company, is making significant strides in the treatment of neurodegenerative diseases through its novel nanotherapeutic platform.…

MondayAug 05, 2024 10:00 am

Study Uncovers How Brain Tumors Evolve During Treatment

Glioblastoma multiforme is one of the most common brain cancers, primarily affecting an individual’s spine and/or brain. This malignant tumor forms from astrocytes, which support nerve cells. These tumors usually grow and spread very quickly, which creates pressure and destroys healthy tissue. In 2008, the glioblastoma multiforme genome was characterized by the Cancer Genome Atlas. Since then, scientists have directed their efforts toward examining transcriptomic and genomic data for new therapeutic targets that will improve patient clinical outcomes. Despite this, the five-year survival rates for this aggressive cancer remain below 5%. In a new study, scientists recently demonstrated how brain…

FridayAug 02, 2024 10:00 am

Data Gaps Which Need to Be Filled in Medicare Advantage

All beneficiaries of Medicare can enroll in Medicare Advantage as an alternative if they need private insurance. Currently, Medicare Advantage makes up over one-half all individuals enrolled in Medicare. Estimates from the Center for American progress show that the Centers for Medicare and Medicaid Services overpays Medicare Advantage plans by between 22% to 39%. This year, overpayments total between $83 billion and $127 billion. This is despite the fact that there’s no substantial evidence that this program promotes health equity for its enrollees or enhances health-care quality. Considering this, there is need for the Centers for Medicare and Medicaid Services…

WednesdayJul 31, 2024 10:00 am

Study Shows Autism More Prevalent in Kids Living in Congested Areas

Cases of neurodevelopmental disorders have increased globally in the last couple of years, with countries such as Italy observing a significant increase in cases of autism, noting that the disorder is more than four times higher in males than females. Autism spectrum disorder affects how individuals interact with others, as well as how they behave, learn and communicate. This disorder is said to have multifactorial origins, with recognized environmental and genetic triggers. Researchers posit that the period between fetal life through early childhood is the most vulnerable time for neurodevelopmental disorders. They argue that during this period, exposure to neurotoxic…

TuesdayJul 30, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces FDA Approval to Transition to New Form of Buntanetap for Future Clinical Trials

Annovis announced in June 2024 that they had filed a composition of matter patent for their new crystal form of buntanetap, along with a provisional patent for the manufacturing process The company’s goal is to use this technology to restore brain function and improve the quality of life for patients dealing with neurodegenerative disease such as Alzheimer’s disease The worldwide market for Alzheimer’s disease modifying drugs, versus symptomatic drugs, could approach $30 billion by 2030 Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders like Alzheimer’s and Parkinson’s, just announced that the U.S.…

MondayJul 29, 2024 10:00 am

Researchers Identify New Gene Behind ALS Onset

Scientists have discovered a new mutation that may cause amyotrophic lateral sclerosis to develop. Amyotrophic lateral sclerosis, or ALS in short, is a neurodegenerative illness that weakens an individual’s muscles and affects their physical function. It starts by degenerating nerve cells in the brain and spinal cord, affecting an individual’s voluntary control of legs and arms. The illness leads to trouble breathing, swallowing and may cause slurred speech. The illness is rare, with an average incidence of 1.4 to 2.4 cases in every 100,000 individuals annually. Additionally, the illness, which is sometimes referred to as motor neuron disease, has no…

FridayJul 26, 2024 10:00 am

Study Highlights Heightened Risk of Diseases Spreading from Animals to Humans

New research has highlighted the increased risk of illnesses spreading to humans from animals. The report by researchers from New York University and Harvard Law School examined common interactions between humans and animals in 15 countries, including the United States. The researchers discovered numerous examples where viruses could spread to humans, explaining that while zoonotic illnesses, including monkeypox and smallpox, had always existed, their prevalence was growing as interactions between animals and humans increased with urban expansion, climate shifts and international travel. In their report, the researchers noted that changes in policy could greatly decrease the risk of illness crossover.…

FridayJul 26, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Discusses Important Developments of CNM-Au8(R) and Its Novel Technology During Xtalks Podcast

Clene’s mission is to transform the treatment of neurodegenerative diseases with a new class of drugs, potentially impacting the lives of millions The company’s uniquely structured gold nanocrystals have the remarkable ability to convert critical energetic metabolites in living cells for the production of ATP, the essential energy currency for cellular functions, offering disease combatting capabilities Clene is currently preparing for Phase 3 clinical trials of CNM-Au8for ALS and MS, following successful early studies Xtalks Life Science Podcast recently featured Karen S. Ho, PhD, Vice President of Translational Medicine for Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial…

ThursdayJul 25, 2024 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Treatments for Underserved Neurological Disorders

PaxMedica is preparing to submit a New Drug Application to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis On June 27th, PaxMedica will have a Type C meeting with the FDA, pivotal for the progress of PAX-101, their leading drug candidate for autism treatment, within the regulatory framework The outcomes of this FDA meeting are crucial, representing a key moment for PaxMedica to demonstrate the therapeutic potential and public health benefits of PAX-101 The global ASD therapeutics market is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, driven by increasing…

WednesdayJul 24, 2024 10:00 am

Prime Day 2024 Is Massive Success for Amazon as American Buyers Spend $14B-Plus

July 16, 2024, marked the beginning of this year’s Amazon Prime Day, which established a new record in online shopping. The annual two-day sale, which ended on July 17, saw consumers in America spend more than $14 billion. This year’s figure represents an 11% rise in consumer spending, as 2023’s total consumer spending stood at $12.7 billion. On the first day of the sale, $7.2 billion was spent by consumers. During the same period in 2023, consumers spent 11.2% less. The momentum grew on day two of the sale, with consumer spending hitting $7 billion. Amazon released a statement confirming…